Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Retatrutide and gut-health claims
A podcast discussion can raise useful questions, but phase 2 retatrutide evidence does not make it an approved general tool for gut health.
STEP UP semaglutide muscle findings
A small STEP UP MRI subgroup found lower thigh fat infiltration and lower measured muscle volume, with sit-to-stand repetitions preserved.
The science behind nose-to-brain peptides
Semax, Selank and oxytocin sprays can reach the brain via the olfactory nerve, but not through any special breathing or injection trick.
Oral Semaglutide and Cognitive Decline Risk
A small elderly-cohort study links oral semaglutide to less cognitive impairment than DPP-4 inhibitors, but a large Alzheimer's trial found no benefit.
Semaglutide Patches Need a Different Needle
New research shows dissolving microneedle patches need different needle designs for semaglutide than for small drugs.
Semaglutide Plus Niacin for Lung Fibrosis
A rat study paired semaglutide with niacin against lung scarring, targeting the NAD+/SIRT1-FOXO3a-Nrf2 pathway. Here is what it does and does not show.
Tirzepatide, GLP-1 Drugs, and Gum Disease
A large propensity-matched study links tirzepatide to lower periodontal disease risk than other GLP-1 drugs in type 2 diabetes.
New Model Explains Tirzepatide's Edge
A modeling study traces tirzepatide's fasting-glucose advantage over semaglutide to greater liver glucose suppression, not beta cells or extra weight loss.
How Trump's GLP-1 price plan works
The US GLP-1 price plan uses several payment channels, so cash offers, Medicare terms and a patient's final cost are not the same.
Can Retatrutide Be Compounded?
FDA says retatrutide cannot be compounded under federal law. Lilly's six lawsuits show why investigational status matters.
What Lilly and Novo's Q2 Results Mean
Lilly beat expectations while Novo stumbled, but the quarter says more about GLP-1 market momentum than individual treatment choice.
Orforglipron: an oral GLP-1 option
Orforglipron is an oral GLP-1 receptor agonist for obesity. Here is what trial evidence shows, and what remains uncertain.